Thomas Patrick Kelly
CIK: 0001410514
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Xenon Pharmaceuticals Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 15, 2026XENE
Xenon Pharmaceuticals Inc.
Exercise(M)Direct7.5K shares- - Sep 30, 2026XENE
Xenon Pharmaceuticals Inc.
Purchase(P)Direct15K shares at avg. $37.32$560K - Oct 15, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
225K shares- - Oct 15, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
30K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise(M) | 7,500 | - | $0 | Direct |
| Sep 30, 2026 | XENE Xenon Pharmaceuticals Inc. | Purchase(P) | 15,000 | $37.32 | $559,740 | Direct |
| Oct 15, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 225,000 | - | - | Direct |
| Oct 15, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 30,000 | - | - | Direct |
1-4 of 4 transactions
About Kelly Thomas Patrick
Kelly Thomas Patrick (SEC CIK 0001410514) files insider reports with the SEC as Chief Financial Officer of Xenon Pharmaceuticals Inc. (XENE).
Signal8 holds 4 ownership filings by Kelly Thomas Patrick (1 Form 3, 3 Form 4), filed between Oct 17, 2025 and Oct 16, 2026. Those filings report 4 transactions, from Oct 15, 2025 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kelly Thomas Patrick's filings is in BURNABY.
Recent filings by Kelly Thomas Patrick
Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)
- MORTIMER IAN, PRESIDENT & CEO
- Svoronos Dawn, Director
- GANNON STEVEN, Director
- PATOU GARY, Director
- Cannon Gillian, Director
- Machado Patrick, Director